Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 2/2007

01-04-2007 | Presidential Symposium II (Review Article)

Magnetic resonance mammography has limited ability to estimate pathological complete remission after primary chemotherapy or radiofrequency ablation therapy

Authors: Seigo Nakamura, Mitsutomi Ishiyama, Hiroko Tsunoda-Shimizu

Published in: Breast Cancer | Issue 2/2007

Login to get access
Metadata
Title
Magnetic resonance mammography has limited ability to estimate pathological complete remission after primary chemotherapy or radiofrequency ablation therapy
Authors
Seigo Nakamura
Mitsutomi Ishiyama
Hiroko Tsunoda-Shimizu
Publication date
01-04-2007
Publisher
Springer Japan
Published in
Breast Cancer / Issue 2/2007
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.2325/jbcs.951

Other articles of this Issue 2/2007

Breast Cancer 2/2007 Go to the issue

Original Article

diagnostic ultrasonography and mammography for invasive and noninvasive breast cancer in women aged 30 to 39 years

Case Report

angiosarcoma arising in the breast following breast-conserving surgery with radiation for breast carcinoma

Review Article

Recent perspectives of endocrine therapy for breast cancer

Review Article

Immunohistochemical assessment of hormone receptor status using a new scoring system (J-score) in breast cancer

Review Article

Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?

Original Article

Percutaneous endoscopy-guided biopsy of an intracystic tumor with a mammary ductoscopy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits